{"organizations": [], "uuid": "414650b22cf0e591ad1175300451bfae48149e3e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530682?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Series B raises $37mm for Proteostasis", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Series B raises $37mm for Proteostasis", "spam_score": 0.0, "site_type": "news", "published": "2015-09-09T02:40:00.000+03:00", "replies_count": 0, "uuid": "414650b22cf0e591ad1175300451bfae48149e3e"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530682?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Series B raises $37mm for Proteostasis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Series B raises $37mm for Proteostasis Deal Date: Sep-01-2015 / Deal # 201530682 Executive Summary \nProteostasis Therapeutics Inc. raised $37mm in its Series B mezzanine financing led by Cormorant Asset Management, which was joined by other new backer Rock Springs Capital Management and returning shareholders New Enterprise Associates, Elan Science One, HealthCare Ventures, Fidelity Biosciences, Novartis Bioventures, Novartis Venture Fund, and Sanofi-Genzyme BioVentures. Leerink Partners was the placement agent. Funds will help move its lead cystic fibrosis candidate into the clinic and will also go towards additional pipeline development.", "external_links": [], "published": "2015-09-09T02:40:00.000+03:00", "crawled": "2015-09-09T18:18:06.532+03:00", "highlightTitle": ""}